Sarepta Therapeutics Inc chart

Last update: 2022-12-30
Key statistics and financials
Revenue per share 10.06
Dividend & YieldN/A$ (N/A)
Beta 1.08
Market capitalization 10.28B
Operating cash flow -262.28M
ESG Scores unknown

Company description

Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; and VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping. The company is also developing AMONDYS 45, a product candidate that uses phosphorodiamidate morpholino oligomer chemistry and exon-skipping technology to skip exon 45 of the dystrophin gene; SRP-5051, a peptide conjugated PMO that binds exon 51 of dystrophin pre-mRNA; SRP-9001, a DMD micro-dystrophin gene therapy program; and SRP-9003, a limb-girdle muscular dystrophies gene therapy program. It has collaboration agreements with F. Hoffman-La Roche Ltd; Nationwide Children's Hospital; Lysogene; Duke University; Genethon; and StrideBio. The company was incorporated in 1980 and is headquartered in Cambridge, Massachusetts.

Sector: Healthcare - Industry: Biotechnology

Financial Ratios
Quick Ratio5.34
Working Capital-0.19
Return On Equity-0.45
Debt To Equity1.18
Fixed Asset Ratio0.01
Fixed Interest Cover-7.07

Financial data

Financial Statements

Cashflow Statement 2018-12-31 2019-12-31 2020-12-31 2021-12-31
Change To Liabilities 90.16M 122.98M 791.43M -65.95M
Total Cashflows From Investing Activities -370.49M 286.73M -121.72M 495.41M
Net Borrowings -33.48M 245.62M 291.15M
Total Cash From Financing Activities 530.15M 642.55M 682.32M 561.57M
Change To Operating Activities -136.64M -102.09M -166.33M 103.2M
Issuance Of Stock 563.63M 401.95M 396.01M 569.33M
Net Income -361.92M -715.08M -554.13M -418.78M
Change In Cash -229M 472.82M 668.07M 613.81M
Effect Of Exchange Rate
Total Cash From Operating Activities -388.66M -456.46M 107.47M -443.17M
Depreciation 11.71M 24.05M 26.46M 37.91M
Change To Account Receivables -19.58M -41.84M -10.46M -51.65M
Other Cashflows From Financing Activities -689k -689k -39k
Change To Netincome 68.91M 300.99M 80.63M 35.76M
Capital Expenditures -61.16M -59.63M -82.2M -38.49M

Income Statement 2018-12-31 2019-12-31 2020-12-31 2021-12-31
Research Development
Income Before Tax -362.61M -713.88M -553.07M -418.95M
Net Income -361.92M -715.08M -554.13M -418.78M
Selling General Administrative 207.76M 284.81M 317.88M 282.66M
Gross Profit -134.9M -236.46M -245.53M -165.84M
Ebit -343.53M -522.12M -564.06M -449.21M
Operating Income -343.53M -522.12M -564.06M -449.21M
Interest Expense -33.71M -30.67M -59.95M -63.52M
Income Tax Expense -692k 1.2M 1.06M -168k
Total Revenue 301.03M 380.83M 540.1M 701.89M
Cost Of Revenue 435.94M 617.29M 785.62M 867.73M
Total Other Income ExpenseNet -19.08M -191.76M 11M 30.26M
Net Income From Continuing Ops -361.92M -715.08M -554.13M -418.78M
Net Income Applicable To Common Shares -361.92M -715.08M -554.13M -418.78M

Balance Sheet Statement 2018-12-31 2019-12-31 2020-12-31 2021-12-31
Total Liabilities 609.8M 1B 2.22B 2.22B
Total Stockholder Equity 1.03B 818.19M 761.76M 928.01M
Other Current Liabilities 34.08M 66.58M 157.52M 154.28M
Total Assets 1.64B 1.82B 2.98B 3.15B
Common Stock 7k 8k 8k 9k
Other Current Assets 48.67M 61.64M 143.43M 100.9M
Retained Earnings -1.58B -2.29B -2.85B -3.21B
Treasury Stock -99k 50k 3k -20k
Cash 370.83M 835.08M 1.5B 2.12B
Total Current Liabilities 173.69M 264.77M 416.03M 452.73M
Other Stockholder Equity -99k 50k 3k -20k
Property, Plant, and Equipment 97.02M 167.55M 282.19M 236.69M
Total Current Assets 1.43B 1.47B 2.49B 2.6B
Net Tangible Assets 1.02B 805.69M 748.13M 913.77M
Net Receivables 62.52M 93.94M 138.58M 171.64M
Accounts Payable 33.83M 68.09M 111.09M 76.74M


Insider Transactions

Here are the insider transactions of stock shares related to Sarepta Therapeutics Inc:

Filer Name Transaction Text Ownership Date Filer Relation Shares
MAYO STEPHEN L.Sale at price 109.92 per share.D2022-11-17Director858
CHAMBERS MICHAEL ANDREWPurchase at price 103.87 - 105.16 per share.D2022-09-14Director57.1k
CHAMBERS MICHAEL ANDREWPurchase at price 108.20 - 108.80 per share.D2022-08-19Director46.17k
BOOR KATHRYN JEANStock Award(Grant) at price 0.00 per share.D2022-06-02Director4.91k
CHAMBERS MICHAEL ANDREWStock Award(Grant) at price 0.00 per share.D2022-06-02Director4.91k
BEHRENS M KATHLEENStock Award(Grant) at price 0.00 per share.D2022-03-07Director2.95k
GRAY MARY ANNStock Award(Grant) at price 0.00 per share.D2022-03-07Director2.95k
BARRY RICHARD JStock Award(Grant) at price 0.00 per share.D2022-03-07Director2.95k
WIGZELL HANS LENNART RUDOLFStock Award(Grant) at price 0.00 per share.D2022-03-07Director2.95k
NICAISE CLAUDE M.D.Stock Award(Grant) at price 0.00 per share.D2022-03-07Director2.95k
CIAMBRONE WILLIAMStock Award(Grant) at price 0.00 per share.D2022-03-07Officer8k
RODINO-KLAPAC LOUISEStock Award(Grant) at price 0.00 per share.D2022-03-07Officer8k
ESTEPAN IAN MICHAELStock Award(Grant) at price 0.00 per share.D2022-03-07Chief Financial Officer8k
BROWN RYAN EDWARDStock Award(Grant) at price 0.00 per share.D2022-03-07General Counsel8k
MAYO STEPHEN L.Stock Award(Grant) at price 0.00 per share.D2022-03-07Director2.95k
BEHRENS M KATHLEENConversion of Exercise of derivative security at price 10.08 per share.D2021-12-15Director5k
GRAY MARY ANND2021-12-10Director967
RODINO-KLAPAC LOUISEPurchase at price 79.33 per share.D2021-11-24Officer3.78k
INGRAM DOUGLAS SPurchase at price 79.94 per share.D2021-11-17Chief Executive Officer25.03k
RODINO-KLAPAC LOUISEStock Award(Grant) at price 0.00 per share.D2021-11-16Officer40k
MAYO STEPHEN L.Stock Award(Grant) at price 0.00 per share.D2021-11-16Director4.29k
BEHRENS M KATHLEENSale at price 85.76 per share.D2021-03-10Director5k
BEHRENS M KATHLEENConversion of Exercise of derivative security at price 42.30 per share.D2021-03-10Director5k
WIGZELL HANS LENNART RUDOLFSale at price 83.51 per share.D2021-03-08Director10k
WIGZELL HANS LENNART RUDOLFConversion of Exercise of derivative security at price 34.92 per share.D2021-03-08Director10k
BEHRENS M KATHLEENStock Award(Grant) at price 0.00 per share.D2021-03-03Director2.73k
MARTIN JOHN CStock Award(Grant) at price 0.00 per share.D2021-03-03Director2.73k
GRAY MARY ANNStock Award(Grant) at price 0.00 per share.D2021-03-03Director2.73k
BARRY RICHARD JStock Award(Grant) at price 0.00 per share.D2021-03-03Director2.73k
WIGZELL HANS LENNART RUDOLFStock Award(Grant) at price 0.00 per share.D2021-03-03Director2.73k
NICAISE CLAUDE M.D.Stock Award(Grant) at price 0.00 per share.D2021-03-03Director2.73k
O NEILL GILMORE NEILStock Award(Grant) at price 0.00 per share.D2021-03-03Officer15k
O NEILL GILMORE NEILStock Award(Grant) at price 0.00 per share.D2021-03-03Officer15k
CIAMBRONE WILLIAMStock Award(Grant) at price 0.00 per share.D2021-03-03Officer15k
RODINO-KLAPAC LOUISEStock Award(Grant) at price 0.00 per share.D2021-03-03Officer15k
RODINO-KLAPAC LOUISEStock Award(Grant) at price 0.00 per share.D2021-03-03Officer15k
ESTEPAN IAN MICHAELStock Award(Grant) at price 0.00 per share.D2021-03-03Chief Financial Officer15k
ESTEPAN IAN MICHAELStock Award(Grant) at price 0.00 per share.D2021-03-03Chief Financial Officer15k
BROWN RYAN EDWARDStock Award(Grant) at price 0.00 per share.D2021-03-03General Counsel15k
BROWN RYAN EDWARDStock Award(Grant) at price 0.00 per share.D2021-03-03General Counsel15k
BRATICA JOSEPHSale at price 165.00 per share.D2020-12-11Chief Financial Officer1.11k
BRATICA JOSEPHConversion of Exercise of derivative security at price 71.45 per share.D2020-12-11Chief Financial Officer1.11k
GRAY MARY ANND2020-12-10Director967
BRATICA JOSEPHSale at price 160.00 per share.D2020-12-08Officer1.12k
BRATICA JOSEPHConversion of Exercise of derivative security at price 29.60 per share.D2020-12-08Officer1.12k

Insider transaction explanations

Insider buying is the legal purchase of shares by a senior executive or director of a company. "Filer Name" corresponds to the name of the stock buyer or seller. "Transaction Text" describes the transaction. "Ownership" gives information about the transaction type. "Date" is the reported transaction date. "Filer Relation" gives the role of the insider in the company. "Shares" is the value of the transaction. You will find the complete description of the General Transaction Codes on the SEC dedicated page


Investment strategy backtesting

These are the result of three automatic investment systems applied to Sarepta Therapeutics Inc. You will find the performance of an systematic investment system, a momentum strategy, and a buy the dip trading strategy.


Systematic investment results on Sarepta Therapeutics Inc

Here is the result of two systematic investment strategies applied to Sarepta Therapeutics Inc. The first strategy automatically buys the first day of the month, and the second strategy buys the fifteenth day of the month.

Systematic investment equity curve on Sarepta Therapeutics Inc

The following chart shows the equity curve of the two systematic investment strategies applied to Sarepta Therapeutics Inc:

Sarepta Therapeutics Inc automated entries

The systematic investment strategy that buys the first day of the month would give a performance of -10.68% on the backtest period.

Performance at glance

Performance

-10.68 %

Latent gain

-238.35 $

Invested capital

2230.89 $

Annualized return

-2.58 %
Build your Trading System
Automated Trading using Prorealtime ebook

Momentum strategy results on Sarepta Therapeutics Inc

This is the result of two momentum investment strategies applied to Sarepta Therapeutics Inc. The first strategy uses a momentum signal calculated on one quarter, and the second uses a momentum signal calculated on two quarters.

Momentum entry openings on Sarepta Therapeutics Inc

The following chart shows all the entries opened by the momentum investment system on Sarepta Therapeutics Inc:

Sarepta Therapeutics Inc momentum entries
  • The first momentum investment strategy would give -0.2% of return on Sarepta Therapeutics Inc. That represents -8.0$ of latent gain with 4083.65$ of employed capital.
  • The second momentum investment strategy would give -13.73% of return on Sarepta Therapeutics Inc. That represents -403.74$ of latent gain with 2939.7$ of employed capital.
Performance at glance (1Q Momentum)

Performance

-0.2 %

Latent gain

-8.0 $

Invested capital

4083.65 $

Annualized return

-9.07 %
Performance at glance (2Q Momentum)

Performance

-13.73 %

Latent gain

-403.74 $

Invested capital

2939.7 $

Annualized return

-3.75 %

Momentum equity curve on Sarepta Therapeutics Inc

The following chart shows the equity curve of the two momentum strategies applied to Sarepta Therapeutics Inc:

Sarepta Therapeutics Inc momentum equity

Note: the dividends potentially given by Sarepta Therapeutics Inc are not integrated into the calculation of the equity curve neither the performance of the strategy. The integration of the dividends will be available soon.


Employed capital on Sarepta Therapeutics Inc

The following chart shows the employed capital evolution of the two momentum strategies on Sarepta Therapeutics Inc since the beginning:

Sarepta Therapeutics Inc

Note: the algorithm buys for a maximum of 250$ per entry. If the stock price is greater than 250$, the system buys only one stock per entry. The investment system stops automatically when the financial exposure reaches 10000$.


Buy the dip strategy result on Sarepta Therapeutics Inc

Buy the dip entry openings on Sarepta Therapeutics Inc

Sarepta Therapeutics Inc

The performance achieved by the robo-advisor on Sarepta Therapeutics Inc is -19.41%. That represents -43.64$ of latent gain with 224.78$ of employed capital. The following chart shows Sarepta Therapeutics Inc stock price with all the entries opened by the automated investment system.

Note: The blue line represents the weekly stock price of Sarepta Therapeutics Inc, and the green triangles represent the entry openings. The artificall robo-advisor needs at least 100 weeks of trading history to work.

Performance at glance

Performance

-19.41 %

Latent gain

-43.64 $

Invested capital

224.78 $

Annualized return

-9.07 %

Equity curve of the strategy applied to Sarepta Therapeutics Inc

The following chart shows the result of the investment strategy applied to Sarepta Therapeutics Inc:

Sarepta Therapeutics Inc

Note: the dividends potentially given by Sarepta Therapeutics Inc are not integrated into the calculation of the equity curve neither the performance of the strategy. The integration of the dividends will be available soon.


Employed capital on Sarepta Therapeutics Inc

The following chart shows the employed capital evolution since the beginning of the investment strategy on Sarepta Therapeutics Inc:

Sarepta Therapeutics Inc

Note: the algorithm buys for a maximum of 250$ per entry. If the stock price is greater than 250$, the system buys only one stock per entry. The investment system stops automatically when the financial exposure reaches 10000$.


Investment strategies comparison on Sarepta Therapeutics Inc

In this section, I will compare the three previous investment strategies applied to Sarepta Therapeutics Inc.

Equity curve comparison on Sarepta Therapeutics Inc

The following chart shows the equity curve of the artificall advisor, the trend folowing and the automatic investment strategies:

Sarepta Therapeutics Inc investment strategy comparison

Employed capital comparison on Sarepta Therapeutics Inc

Sarepta Therapeutics Inc investment comparison

Performance comparison on Sarepta Therapeutics Inc

Strategy Latent Profit Growth Employed capital CAGR
Automatic investment -10.68% -238.35$ 2230.89$ -2.58%
Momentum 1 quarter -0.2% -8.0$ 4083.65$ -0.05%
Momentum 2 quarters -13.73% -403.74$ 2939.7$ -3.75%
Non-directional -19.41% -43.64$ 224.78$ -9.07%
Annualized return comparison

Automatic investment

-2.58 %

Momentum 1Q

-3.75 %

Momentum 2Q

-3.75 %

Non-directional

-9.07 %

Correlated stocks

Here are the most positively and negatively correlated stocks with Sarepta Therapeutics Inc:

Negative correlation

Most negatively correlated stocks this year


Most negatively correlated stocks last 3 months

  • Borr Drilling Ltd
  • TSE SUI LUEN
  • BE ENVIRONMENT

  • Note: The algorithm computes the probability of correlation between Sarepta Therapeutics Inc and the other stocks. There may be false positives or some missing correlated stocks. If the price of Sarepta Therapeutics Inc does not vary for 36 weeks, the correlation calculation result will be wrong.


    Company information

    Company name Sarepta Therapeutics Inc
    Country United States
    City Cambridge
    Address 215 First Street
    Phone 617 274 4000
    Website www.sarepta.com
    FullTime employees 840
    Industry Biotechnology
    Sector Healthcare
    Exchange XNAS
    Ticker SRPT
    Market www.nasdaq.com

    Sarepta Therapeutics Inc ESG Scores

    Environment scores

    Environment ESG Factors Scores
    Environment Score 0
    Peer Environment Performance unknown
    Environment Percentile unknown
    Palm Oil unknown
    Nuclear unknown
    Fur Leather unknown
    GMO unknown
    Coal unknown
    Pesticides unknown
    Animal Testing unknown

    Social scores

    Social ESG Factors Scores
    Social Score 0
    Peer Social Performance unknown
    Social Percentile unknown
    Highest Controversy unknown
    Peer Highest Controversy Performance unknown
    Adult unknown
    Gambling unknown
    Alcoholic unknown
    Tobacco unknown
    Catholic unknown
    Controversial Weapons unknown
    Small Arms unknown
    Military Contract unknown
    Peer Count unknown

    Related Controversy:


    Governance scores

    Governance ESG Factors Scores
    Governance Score 0
    Peer Governance Performance unknown
    Governance Percentile unknown

    ESG at glance
    Total ESG Scores: unknown
    Environment Score: 0
    Social Score: 0
    Governance Score: 0

    ESG Performance: unknown

    Peer Group: unknown

    Peer Esg Score Performance: unknown

    Rating Year: unknown

    Rating Month: unknown

    Max Age: unknown

    Percentile: unknown